Farglitazar

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Farglitazar
Farglitazar.svg
Clinical data
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC34H30N2O5
Molar mass546.612 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Farglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.

References[edit]